The impact of PET/CT in the management of recurrent ovarian cancer. (Q53542100)

15 May 2018

title

The impact of PET/CT in the management of recurrent ovarian cancer. (English)

1 reference

15 May 2018

1 reference

3

1 reference

15 May 2018

Rodney J. Hicks

6

1 reference

15 May 2018

author name string

Bryony Simcock

1

1 reference

15 May 2018

Deborah Neesham

2

1 reference

15 May 2018

Elisabeth Drummond

4

1 reference

15 May 2018

Alvin Milner

5

1 reference

15 May 2018

language of work or name

English

0 references

publication date

19 April 2006

1 reference

15 May 2018

published in

Gynecologic Oncology

1 reference

15 May 2018

volume

103

1 reference

15 May 2018

issue

1

1 reference

15 May 2018

page(s)

271-276

1 reference

15 May 2018

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Epidemiology of ovarian cancer: a status report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

The use of PET scanning in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Clinical value of positron emission tomography with FDG for recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

[18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Second thoughts about second-look laparotomy in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2006.03.004

10.1016/J.YGYNO.2006.03.004

7 January 2021

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018